Cairo Pharmaceuticals results, Q4 2023
Net profit, assets, equity and cash flow for Q4 2023, against the same period a year earlier, from the published financial statements. fiscal year starts in July.
Net profit41.04 millionEGP · +179.0% vs the same period a year earlier
Total assets1.26 billionEGP · +7.9% vs the same period a year earlier
Shareholders' equity686 millionEGP · −13.5% vs the same period a year earlier
Operating cash flow74.83 millionEGP · +63.6% vs the same period a year earlier
In short
- Cairo Pharmaceuticals's net profit for Q4 2023 was about 41.04 million EGP, up +179.0% from 14.71 million EGP in Q4 2022.
- Total assets at the end of Q4 2023 were about 1.26 billion EGP, and shareholders' equity about 686 million EGP.
- Operating cash flow for Q4 2023 was positive at 74.83 million EGP.
Key lines against the same period a year earlier
This periodQ4 2022Change
Net profit41.04 million14.71 million+179.0%
Gross profit99.29 million62.16 million+59.7%
Total assets1.26 billion1.17 billion+7.9%
Total liabilities575 million375 million+53.3%
Shareholders' equity686 million794 million−13.5%
Total liabilities and equity1.26 billion1.17 billion+7.9%
Operating cash flow74.83 million45.73 million+63.6%
Investing cash flow-12.51 million4.21 million−397.2%
Financing cash flow-16.24 million-4.59 million−254.1%
Net change in cash46.07 million45.36 million+1.6%
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. Figures are as shown in the published statement summary; quarterly figures may be cumulative from the start of the fiscal year.
Cairo Pharmaceuticals's Q1 2027 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy